MNKD

Afrezza® (insulin human) Inhalation Powder

Type 1 or Type 2 diabetes (Adults)

Quarterly Sales (Approved)

Exp Date

February 26, 2021 (Est)

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Afrezza® for  Type 1 or Type 2 diabetes (Adults) - Quarterly Sales (Approved)


WHAT IS THE NEXT CATALYST EVENT?

  • Quarterly Sales


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • February 26, 2021 (Est)


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION

  • Insulin lowers blood glucose levels by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in adipocytes, inhibits proteolysis, and enhances protein synthesis.

Updated by HC

MNKD, Afrezza, insulin human Inhalation Powder, Type 1 or Type 2 diabetes Adults, blood sugar glucose

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon